We tend to think that it is the big, expensive advances in medicine that matter. In Obstetric Medicine, appropriate and consistent attention to a few simple but common issues could have significant impact on women with actual or suspected medical problems in pregnancy. The older I get the more frustrated I become that these simple interventions evade us.
All women have their blood pressure measured and their urine dipped in early pregnancy, and then at regular intervals throughout pregnancy. The rationale for this monitoring is to diagnose hypertensive disorders in pregnancy and screen for and diagnose pre-eclampsia. Yet, the presence of new onset isolated proteinuria is often taken as an indication of possible urine infection, and a common response is to request urine culture rather than urine protein quantification. Subsequent visits are not brought forward, and the opportunity to diagnose pre-eclampsia is missed. Persistent proteinuria from early pregnancy can indicate underlying renal disease and again assumption that this relates to urine infection means the opportunity to diagnose chronic kidney disease is missed. Indeed, a woman included in the last MBRRACE report of maternal deaths in the UK died from lupus nephritis that presented with antenatal proteinuria and could have been diagnosed and treated antenatally. 1 Similarly, the significance of a booking blood pressure that is 'normal' (5140/90 mmHg) yet abnormally high for the first trimester, for example, 135/85 mmHg, is often missed. Such women almost certainly have pre-existing hypertension of which they are often not aware. When such women become hypertensive later in pregnancy, either labeled gestational/pregnancy-induced hypertension or develop pre-eclampsia, their management postpartum particularly the need to continue anti-hypertensive agents long term is sub-optimal and the opportunity to counsel them about their long-term health is missed.
These errors of omission should be easy to correct; the errors of over-medicalization, over-investigation and over-treatment are more challenging. My three pet hates. Over-medicalization -telling women with anti-phospholipid antibodies that they have anti-phospholipid syndrome with all its attendant risks and that they need to inject themselves with heparin throughout pregnancy. Over-investigationrequesting computer tomography pulmonary angiography for all women who present with chest pain or breathlessness in pregnancy without taking a proper focused history, performing or heeding the examination findings or performing a chest X-ray. Over-treatmenttelling all women with hypothyroidism that they need to increase their dose of thyroxine in pregnancy and that their thyroid-stimulating hormone should be less than 2.5 mU/L (or even less than 1.0 mU/L); or worse, telling women with sub-clinical hypothyroidism the same or telling women with an isolated TSH of 3 U/L that they require thyroxine and without it they are risking harm to their unborn child. Perhaps, you have your own frustrations? We would like to hear and publish these in our letters page.
This issue includes four excellent review articles. Two cover rare but important complications which are frequently misdiagnosed -monogenic diabetes and acute respiratory failure. The failure to recognize and appropriately treat acute respiratory failure in pregnancy was highlighted in the confidential enquiries into maternal deaths in the UK. 1 Perhaps, just as important is the failure to realize that respiratory symptoms and signs can indicate cardiac disease. This is the subject of the case report of Varnier et al. 'All that wheezes is not asthma: A cautionary case study of shortness of breath in pregnancy'. 2 The other two review articles deal with more common issues. Restless leg syndrome, like so many of the 'normal symptoms of pregnancy', 3 is poorly understood and not widely researched. D'Ambrosio et al. offer useful insights. The review by Gaudet 4 on gestational weight gain and the associated increase in adverse pregnancy outcomes is very timely given the recent publication of the UK Pregnancies Better Eating and Activity Trial (UPBEAT). 5 This multicenter UK study randomized 1555 obese (mean BMI 36) women to standard antenatal care or a behavioural intervention of health trainer-led group or individual sessions of 1 hr duration once a week for eight weeks aimed at improving glucose tolerance through dietary and physical activity behaviour change. The primary outcomes of gestational diabetes (25%-26%) and large for gestational age infants (8%-9%) were no different between the groups. However, the complex intervention was effective at improving diet quality and physical activity, reducing gestational weight gain (by 0.5 kg) and decreasing surrogate measures of maternal body fatness.
Perhaps, the most important article in this quarter's issue is that by Tabassum Firoz and colleagues 'Obstetric medicine: Collaborating towards global progress in maternal health'. 6 This summarizes many of the issues discussed at the global obstetric medicine workshop at the ISOM meeting in New Orleans last year. It describes the degree of development of obstetric medicine in different low and middle income countries (LMIC), and it behoves all of us to reflect on the huge developments that have been made in resource poor settings, and the message of the article is very much how we can learn from each other.
